



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

On re Application of: AMTMANN, Eberhard  
Serial No.: 10/820,121  
Filed: April 8, 2004  
Title: SALTS OF GUANIDINE DERIVATIVES AND PHARMACEUTICAL  
PREPARATIONS CONSISTING THEREOF  
Group: 1614  
Examiner:  
Attorney Ref.: PAT 2293AW-2 US

July 8, 2004

Commissioner for Patents  
U.S. Patent and Trademark Office  
220 20th Street S.  
Mail Stop Amendment  
Crystal Plaza Two, Lobby, Room 1B03  
Arlington VA 22202  
U.S.A.

Dear Sir

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to 37 C.F.R. §§ 1.97 and 1.98 , the applicant hereby submits an  
Information Disclosure Statement for consideration by the Examiner.

**I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION**

The patents, publications, or other information submitted for consideration by  
the Office are listed on the PTO-1449, attached hereto.

**II. COPIES**

**(check at least one box)**

- ☐ a. Submitted herewith is a legible copy of (i) each U.S. and foreign patent  
and application; (ii) each publication or that portion which caused it to  
be listed; and (iii) all other information or that portion which caused it to  
be listed.
- ☒ b. As this application was filed after June 30, 2003, no U.S. patent or  
published application copies are enclosed. Where applicable,  
submitted herewith is a legible copy of (i) each foreign patent or  
application; (ii) each publication or that portion which caused it to be  
listed; and (iii) all other information or that portion which caused it to be  
listed.

- ☐ c. Some or all of the documents listed on the PTO-1449 are not enclosed because they were cited in the International Search Report and copies should already be in the PTO file. If copies are needed, please contact the undersigned.

### **III. CONCISE EXPLANATION OF THE RELEVANCE**

**(check at least one box)**

- ☒ a. DOCUMENTS IN THE ENGLISH LANGUAGE  
The attached patents, publications, or other information in the English language do not require a statement of relevancy.
- ☒ b. DOCUMENTS NOT IN THE ENGLISH LANGUAGE  
A concise explanation of the relevance of all patents, publications, or other information listed that is not in the English language is as follows:  
See attached Schedule A.
- ☐ c. ENGLISH LANGUAGE SEARCH REPORT  
An English language version of the search report or action that indicates the degree of relevance found by the foreign Patent Office is attached, thereby satisfying the requirement for a concise explanation. See MPEP 609(A) (3).
- ☐ d. OTHER  
The following additional information is provided for the Examiner's consideration.  
English Abstracts are provided where available.

### **IV. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97 (b):**

**(check one box)**

- ☐ a. Within three months of the filing date of a national application (37 C.F.R. § 1.97 (b) (1)). No fee or statement is required. (This section is not to be used with RCE's AND CPA's.)
- ☐ b. Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application (37 C.F.R. § 1.97 (b) (2)). No fee or statement is required.
- ☐ c. Concurrently with the filing of a Continued Prosecution Application under 37 C.F.R. § 1.53 (d) or concurrently with the filing of a Request for Continued Examination under § 1.114 (37 C.F.R. § 1.97 (b) (4)). No fee or statement is required.

- ☒ d. Before the mailing date of a first Action on the merits (37 C.F.R. § 1.97 (b) (3)). No fee or statement is required. In the event that a first Office Action on the merits has been issued, please consider this IDS under 37 C.F.R. § 1.97 (e) below, or, if no statement has been made, charge our deposit account in the amount of **\$180.00** as required by 37 C.F.R. § 1.17 (p).

**V. THIS IDS IS BEING FILED UNDER 37 C.F.R. § 1.97 (c):  
(check one box)**

- ☐ a. No statement; therefore, a fee in the amount of **\$180.00** as required by 37 C.F.R. § 1.17 (p).
- ☐ b. See the statement below. No fee is required.

**VI. STATEMENT UNDER 37 C.F.R. § 1.97 (e)  
(check only one box)**

The undersigned hereby states that

- ☐ a. Each item of information contained in the IDS was first cited in any communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS; or
- ☐ b. No item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of IDS was known to any individual designated in 37 C.F.R. § 1.56 (c) more than three months prior to the filing of the IDS.
- ☐ c. Some of the items of information were cited in a communication from a foreign Patent Office. As to this information, the undersigned states that each item of information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart foreign application not more than three months prior to the filing of this IDS. As to the remaining information, the undersigned hereby states that no item of this remaining information contained in the IDS was cited in a communication from a foreign Patent Office in a counterpart from a foreign Patent Office in a counterpart foreign application and, to the best of my knowledge after making reasonable inquiry, was known to any

individual designated in the 37 C.F.R. § 1.56 (c) more than three months prior to the filing of this statement.

**VII. PAYMENT OF FEES**

**(check one box)**


- ☐ Please charge Deposit Account No. 501593 in the amount required by 37 C.F.R. § 1.17 (p) for the above-indicated fee. A duplicate copy of this paper is attached.
- ☒ No fee is required.

If the Examiner has any questions concerning this IDS, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 501593.

**If the preceding amount is incorrect, any deficiency or overpayment should also be charged or credited to Deposit Account No. 501593, in the name of Borden Ladner Gervais LLP.**

Respectfully submitted,

Eberhard AMTMANN



By: **Gail C. Silver**

Registration No. **47,945**

**BORDEN LADNER GERVAIS LLP**

World Exchange Plaza

1100-100 Queen Street

Ottawa ON K1P 1J9

Telephone 613-237-5160

Facsimile 613-787-3558

E-mail [ipott@blgcanada.com](mailto:ipott@blgcanada.com)

GCS/AAB/aab

Encls.

- ☒ Schedule A
- ☒ PTO-1449
- ☒ 17 References
- ☒ Foreign Search Report

**SCHEDULE A - DOCUMENTS NOT IN THE ENGLISH LANGUAGE**

1. DE 1802394 English language abstract provided.
2. DD 286580 Amidinohydrazone-2-substituted benzophenones are disclosed in Formula I as shown in Table 1 on page 4. Additional salts are disclosed in Table 2 on page 6.
3. DE 1238896 English language corresponding U.S. Patent No. 3,383,932 is provided.
4. WO 97/45901 Corresponding English language U.S. Patent No. 6,284,798 is provided.



<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>Complete if Known</b>	
				Application No.: 10/820,121	
				Filing Date: April 8, 2004	
				First Named Inventor: Eberhard AMTMANN	
				Group Art Unit: 1614	
Examiner Name:					
Sheet	1	of	2	Attorney Docket No.: PAT 2293AW-2	

### U.S. PATENT DOCUMENTS

Examiner Initials	Cite No.	Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		3,915,918	10/28/1975	Springle et al.	

### FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No.	Patent Document No.	Date of Publication mm-dd-yyyy	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T	Check if English Translation is attached
						√	
		DE 1802394	05/08/1969	American Home Products Corp.		√	
		DD 286580	08/09/1984	Institut fur Pharmakologische Forschung			
		GB 1257270	12/15/1971	Suddeutsche Kalkstickstoff-Werke A.G.			
		GB 950,693	02/26/1964	Shell Internationale Research Maatschappij N.V.			

### OTHER DOCUMENTS

--	--	--

Examiner Signature:	Date Considered:
<i>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.</i>	



<b>Form PTO-1449</b>  <b>INFORMATION DISCLOSURE STATEMENT</b>				<b>Complete if Known</b>	
				Application No.:	10/820,121
				Filing Date:	April 8, 2004
				First Named Inventor:	Eberhard AMTMANN
				Group Art Unit:	1614
				Examiner Name:	
Sheet	2	of	2	Attorney Docket No.:	PAT 2293AW-2

		GB 842,325	07/27/1960	Imperial Chemical Industries Limited			
		EP 0188333	07/23/1986	Syntex (U.S.A.) Inc.			
		WO 84/01490	04/26/1984	Wheatley Chemical Company Limited			
		DE 1238896	04/20/1967	Farbenfabriken Bayer AG			√*
		GB 1475073	06/01/1977	Reckitt & Colman Products Limited			
		GB 1091049	11/15/1967	Calgon Corporation			
		GB 932,951	07/31/1963	May & Baker Limited			
		GB 768,089	02/13/1957	Farbenfabriken Bayer AG			
		EP 0315467	05/10/1989	Lyphomed, Inc.			
		WO 97/45401	12/04/1997	Amtmann et al.			√*

### OTHER DOCUMENTS

		Chemical Abstract of Japanese Patent, JP 11035546, 02/09/1999. vol. 130, Ref. 213456
		Chemical Abstract, "The Effect of some oligoamines and -guanidines on membrane permeability in higher plants", vol. 97, Ref. 124283.
		Chemical Abstract, "Formation of salts by reaction of benzamidine with 2-bromo methyl alkanoates", vol. 85, Ref. 32586.

<b>Examiner Signature:</b>	<b>Date Considered:</b>
<b>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if in conformance and not considered. Include copy of this form with next communication to applicant.</b>	

\* Corresponding English language patents are provided.